Value proposition

True precision medicine through single-cell science.

True precision medicine through single-cell science.

Scailyte, a pioneer in AI-driven biomarker discovery from single-cell omics data, has leveraged its proprietary AI platform, ScaiVision, to analyze over 60 million single-cell profiles. The company's extensive network of clinical partners and access to unique patient cohorts in oncology and auto-immunity have led to the development of multiple patent-pending biomarker signatures. Headquartered in Basel, Switzerland, Scailyte collaborates with clinical-stage biotech and pharma companies worldwide, enabling biomarker-driven drug development and paving the way for precision medicine to become a reality.

If you want to partner with, reach out to contact@scailyte.com

More information about our company, technology & services you can find on our website - https://scailyte.com

artificial intelligence, diagnostics, single-cell, medtech, biomarker, big data, clinical research, data analysis, software, and cytometry